Effect of chronic administration of mestranol, tamoxifen, and toremifene on hepatic ploidy in rats

Toxicological Sciences

Volumn 43, Issue 2, 1998, Pages 129-138

  Dragan, Y P ^a   Shimel, R J ^a   Bahnub, N ^a   Sattler, G ^a   Vaughan, J R ^a   Jordan, V C ^b   Pitot, H C ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTROGEN; MESTRANOL; TAMOXIFEN; TOREMIFENE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER INCIDENCE; CONTROLLED STUDY; DRUG EFFECT; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CELL CULTURE; LIVER TOXICITY; LONG TERM EXPOSURE; NONHUMAN; ORAL DRUG ADMINISTRATION; PLOIDY; RAT;

ANIMALIA;

EID: 0031879099     PISSN: 10966080     EISSN: None     Source Type: Journal    
DOI: 10.1006/toxs.1998.2464     Document Type: Article

References (115)

1. Aldaz, C., Conti, C., Klein-Szanto, A., and Slaga, T. (1987). Progressive dysplasia and aneuploidy are hallmarks of mouse skin papillomas: Relevance to malignancy. Proc. Natl. Acad. Sci. USA 84, 2029-2032.
2. Becker, F., Fox, R., Klein, K., and Wolman, S. (1971). Chromosome patterns in rat hepatocytes during N-2-fluorenylacetamide carcinogenesis. J. Natl. Cancer Inst. 46, 1261-1269.
3. Brodsky, W., and Uryvaeva, I. (1977). Cell polyploidy: Its relation to tissue growth and function. Int. Rev. Cytol. 50, 277-332.
4. Busch, H. (1997). Adducts and tamoxifen. Semin. Oncol 24(Suppl. 1), 1-104.
5. Carriere, R. (1962). Role of the thyroid gland in the control of polyploid cell formation in the rat liver. Endocrinology 70, 761-763.
6. Carriere, R. (1969). The growth of liver parenchymal nuclei and its endocrine regulation. Int. Rev. Cytol. 50, 201-276.
7. Carthew, P., Martin, E., White, I., De Matteis, F., Edwards, R., and Smith, L. L. (1995). Tamoxifen induces short-term cumulative DNA damage and liver tumors: Promotion by phenobarbital. Cancer Res. 55, 544-557.
8. Carthew, P., Nolan, B. M., Edwards, R. E., and Smith, L. L. (1996). The role of cell death and cell proliferation in the promotion of rat liver tumours by tamoxifen. Cancer Lett. 106, 163-169.
9. Castelain, P., Deleener, A., Kirsch-Volders, M., and Barbason, H. (1989). Cell population kinetics and ploidy rate of early focal lesions during hepatocarcinogenesis in the rat. Br. J. Cancer 60, 827-833.
10. Colletta, A. A., Benson, J. R., and Baum, M. (1994). Alternative mechanisms of action of anti-oestrogens. Breast Cancer Res. Treat. 31, 5-9.
11. Cunningham, A., Klopman, G., and Rosenkranz, H. (1996). A study of the structural basis of the carcinogenicity of tamoxifen, toremifene, and their metabolites. Mutat. Res. 349, 85-94.
12. Daniel, P., Gaskell, S., Bishop, H., Campbell, C., and Nicholson, R. (1981). Determination of tamoxifen and biologically active metabolites in human breast tumors and plasma. Eur. J. Clin. Oncol 17, 1183-1189.
13. Danielsen, H., Lindmo, T., and Reith, A. (1986). A method for determining ploidy distributions in liver tissue by stereological analysis of nuclear size calibrated by flow cytometric DNA analysis. Cytometry 7, 475-480.
14. Davies, A., Martin, E., Jones, R., Lim, C., Smith, L., and White, I. (1995). Peroxidase activation of tamoxifen and toremifene resulting in DNA damage and covalently bound protein adducts. Carcinogenesis 16, 539-545.
15. DeGregorio, M., Coronado, E., and Osborne, C. (1989). Tumor and serum tamoxifen concentrations in the athymic nude mouse. Cancer Chemother. Pharmacol. 23, 68-70.
16. Deleneer, A., Castelain, Ph., Preat, V., de Gerlache, J., Alexandre, H., and Kirsch-Volders, M. (1987). Changes in nucleolar transcriptional activity and nuclear DNA content during the first steps of rat hepatocarcinogenesis. Carcinogenesis 8, 195-201.
17. Digernes, V. (1980). Nuclear ploidy of the growing mouse liver: Age variations and effects of a carcinogen (dimethylnitrosamine). Flow Cytometry 4, 300-303.
18. Digernes, V., and Iversen, O. (1984). Flow cytometry of nuclear DNA content in liver cirrhosis and liver tumors in rats exposed to acetylaminofluorene. Virchows Arch. Cell. Pathol. 47, 139-146.
19. Doljanski, F. (1960). The growth of the liver with special reference to mammals. Int. Rev. Cytol. 17, 217-241.
20. Dragan, Y., Sargent, L., Xu, Y.-D., Xu, Y.-h., and Pitot, H. C. (1993). The initiation-promotion-progression model of rat hepatocarcinogenesis. Proc. Soc. Exp. Biol. Med. 202, 16-24.
21. Dragan, Y., Fahey, S., Street, K., Vaughan, J., Jordan, V. C., and Pitot, H. C. (1994). Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats. Breast Cancer Res. Treat. 31, 11-25.
22. Dragan, Y., Singh, J., and Pitot, H. C. (1996). Effect of the separate and combined administration of mestranol and phenobarbital on the development of altered hepatic foci expressing placental form of glutathione S-transferase in the rat. Carcinogenesis, 17, 2043-2052.
23. Dragan, Y., Vaughan, J., Jordan, V. C., and Pitot, H. C. (1995). Comparison of the effects of tamoxifen and toremifene on liver and kidney tumor promotion in female rats. Carcinogenesis 16, 2733-2741.
24. Early Breast Cancer Trialists' Collaborative Group (1992). Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339, 1-15; 71-85.
25. Epstein, C. (1967). Cell size, nuclear content, and the development of polyploidy in the mammalian liver. Proc. Natl. Acad. Sci. USA 57, 327-334.
26. Fischer, B., Constantino, J., Redmond, C., and other members of the NSABP (1989). A randomized clinical trial evaluating tamoxifen in the treatment of patients with node negative breast cancer who have estrogen-receptor positive tumors. N. Engl. J. Med. 320, 479-484.
27. Gabrielsson, B., Carmignac, D., Flavell, D., and Robinson, I. (1995). Steroid regulation of growth hormone (GH) receptor and GH-binding protein messenger ribonucleic acids in the rat. Endocrinology 136, 209-217.
28. Gahan, P. (1977). Increased levels of euploidy as a strategy against rapid ageing in diploid mammalian systems. Exp. Gerontol. 12, 113-116.
29. Gerlyng, P., Grotmol, T., and Seglen, P. (1994). Effect of 4-acetylaminofluorene and other tumor promoters on hepatocellular growth and binucleation. Carcinogenesis 15, 371-379.
30. Ghia, M., and Mereto, E. (1989). Induction and promotion of γ-glutamyltranspeptidase positive foci in the livers of female rats treated with ethinyl estradiol, clomiphene, tamoxifen, and their associates. Cancer Lett. 46, 195-202.
31. Godoy, H., Judah, D., Arora, H., Neal, G., and Jones, G. (1976). The effects of prolonged feeding with aflatoxin B1 on adult rat liver. Cancer Res. 36, 2399-2407.
32. Gonzales-Mujica, F., and Mathias, A. (1973). Studies of nuclei separated by zonal centrifugation from liver of rats treated with thioacetamide. Biochem. J. 132, 163-183.
33. Gottardis, M., Robinson, S., Satswaroop, P., and Jordan, V. C. (1988). Contrasting action of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res. 48, 812-815.
34. Grandishar, W., and Jordan, V. C. (1997). The clinical potential of new antiestrogens. J. Clin. Oncol. 15, 840-852.
35. Greaves, P., Gooentilleke, R., Nunn, G., Topham, J., and Orton, T. (1993). Two year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats. Cancer Res. 53, 3919-3924.
36. Haesen, S., Derijcke, T., Deleener, A., Castelain, P., Alexandre, H., Preat, V., and Kirsch-Volders, M. (1988). The influence of phenobarbital and butylated hydroxytoluene on the ploidy rate in rat hepatocarcinogenesis. Carcinogenesis 9, 1755-1761.
37. Hard, G., Iatropoulos, M., Jordan, K., Radi, L., Kaltenberg, O., Imondi, A., and Williams, G. (1993). Major differences in the hepatocarcinogenicity and DNA adduct forming ability between tamoxifen and toremifene in female Crl:CD (BR) rats. Cancer Res. 53, 3919-3924.
38. Hayes, D., Van Zyl, J., and Hacking, A. (1995). Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J. Clin. Oncol. 113, 2556-2566.
39. Hirsamaki, P., Hirsamaki, Y., Nieminen, L., and Payne, B. (1993). Tamoxifen induces hepatocellular carcinomas in rat liver: A one year study with two antiestrogens. Arch. Toxicol. 67, 49-54.
40. Irving, C., Roszell, J., and Fredi, J. (1977). Effects of chronic feeding of 2-acetylaminofluorene on nuclear populations in rat liver. Adv. Enzyme Regul. 16, 365-377.
41. Jordan, V. C. (1994). Long-Term Tamoxifen Therapy for Breast Cancer. University of Wisconsin Press, Madison, WI.
42. Jordan, V. C., and Assikis, V. (1995). Endometrial carcinoma and tamoxifen: Clearing up a controversy. Clin. Cancer Res. 1, 467-472.
43. Kallio, S., Kangas, L., and Blanco, G. (1986). A new triphenylethylene compound, Fc-1157a. II. Antitumor effects. Cancer Chemother. Pharmacol. 17, 109-117.
44. Kangas, L., Niemen, A., and Blanco, G. (1986). A new triphenylethylene compound, Fc-1157a. I. Hormonal effects. Cancer Chemother. Pharmacol. 17, 103-108.
45. Karlsson, S., Hirsamaki, Y., Mantyla, E., Nieminen, L., Kangas, L., Hirsimaki, P., Perry, C., Mulhern, M., Millar, P., Handa, J., and Williams, G. (1996). A two-year dietary carcinogenicity study of the antiestrogen toremifene in Sprague-Dawley rats. Drug Chem. Toxicol. 19, 245-266.
46. Kelly, M., Styles, J., and Pritchard, N. (1990). Analysis of cytological changes in hepatocytes from rats dosed with 3′-methyl-4-dimethylaminobenzene: Initial responses appear to involve cytokinesis of binucleated cells. Cancer Lett. 53, 1-3.
47. Kendall, M., and Rose, D. (1992). The effect of diethylstilbesterol, tamoxifen, and toremifene on estrogen-inducible hepatic protein and estrogen receptor proteins in female rats. Toxicol. Appl. Pharmacol. 114, 127-131.
48. Kuramochi, H. (1996). Conformational studies and electronic structures of tamoxifen and toremifene and their electronic carbocations proposed as reactive intermediates leading to DNA adduct formation. J. Med. Chem. 39, 2877-2886.
49. Laird, A., and Barton, A. (1961). Cell proliferation in precancerous liver: Relation to presence and dose of carcinogen. J. Natl. Cancer Inst. 27, 827-839.
50. Lalwani, N., Dethloff, L., Haskins, J., Robertson, D., and de la Iglesia, F. (1997). Increased nuclear ploidy, not cell proliferation, is sustained in the peroxisome proliferator-treated rat liver. Toxicol. Pathol. 25, 165-176.
51. Lerner, L. J., and Jordan, V. C. (1990). Development of antiestrogens and their use in breast cancer: Eighth Cain Memorial Lecture. Cancer Res. 50, 4177-4189.
52. Leuchtenburger, C., Helweg-Larsen, H., and Murmanis, L. (1959). Relationship between hereditary pituitary dwarfism and the formation of multiple deoxyribose nucleic acid (DNA) classes in mice. Lab. Invest. 3, 245-261.
53. Li, D., Dragan, Y., Jordan, V. C., Wang, M., and Pitot, H. C. (1997). Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus. Cancer Res. 57, 1438-1441.
54. Lien, E., Solheim, E., and Veland, P. (1991). Distribution of tamoxifen and its metabolites in rat and human tissues during steady state treatment. Cancer Res. 51, 4837-4844.
55. Love, R., Mazess, R., Barden, H., Epstein, S., Newcombe, P., Cameron, L., Leventhal, H., Jordan, V. C., Feyzi, J., and DeMets, D. (1991). Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann. Int. Med. 115, 860-864.
56. Love, R., Mazess, R., Barden, H., Epstein, S., Newcomb, P., Jordan, V., Carbone, P., and DeMets, D. (1992). Effects of tamoxifen on bone mineral density in post-menopausal women treated with breast cancer. N. Engl. J. Med. 326, 852-856.
57. Lui, J., Lui, Y., Barter, R., and Klaassen, C. (1995). Alteration of thyroid homeostasis by UDP-glucuronylsyltransferase inducers in rats: A dose response study. J. Pharmacol. Exp. Ther. 273, 977-985.
58. Malaab, S., Pollack, M., and Goodyer, C. (1992). Direct effects of tamoxifen on growth hormone secretion by pituitary cells in vitro. Eur. J. Cancer 28A, 788-793.
59. McDonald, C., Alexander, F., Whyte, B., et al. (1995). Cardiac and vascular morbidity in women receiving adjuvant breast cancer in a randomized trial. Br. Med. J. 311, 977-980.
60. Medvedev, Z. (1986). Age-related polyploidization of hepatocytes: The cause and possible role. A minireview. Exp. Gerentol. 21, 277-282.
61. Melchiorri, C., Chieco, P., Zedda, A., Coni, P., Ledda-Columbano, G., and Columbano, A. (1993). Ploidy and nuclearity of rat hepatocytes after compensatory regeneration or mitogen-induced liver growth. Carcinogenesis 14, 1825-1830.
62. Mendecki, J., Dillmann, W., Wolley, W., Oppenheimer, J., and Koss, L. (1978). Effect of thyroid hormone on the ploidy of rat liver nuclei as determined by flow cytometry. Proc. Soc. Exp. Biol. Med. 158, 63-67.
63. Metzler, M., and Schiffmann, D. (1991). Structural requirements for the in vitro transformation of Syrian hamster embryo cells by stilbene estrogens and triphenylethylene type antiestrogens. Am. J. Clin. Oncol. 14, S30-S35.
64. Miller, R., Shah, R., Cattley, R., and Popp, J. (1996). The peroxisome proliferators, WY-14,643 and methylclofenapate induce hepatic ploidy alterations and ploidy-specific DNA synthesis in F344 rats. Toxicol. Appl. Pharmacol. 138, 317-323.
65. Mishkin, S., Farber, E., Ho, R., Mulay, S., and Mishkin, S. (1983). Evidence for the hormonal dependency of hepatic hyperplastic nodules: Inhibition of malignant transformation after endogenous β estradiol and tamoxifen. Hepatology 3, 308-316.
66. Montandon, F., and Williams, G. (1994). Comparison of DNA reactivity of the polyphenylethylene hormone agents diethylstilbesterol, tamoxifen, and toremifene in rat and hamster liver. Arch. Toxicol. 68, 272-275.
67. Mossin, L., Blankson, H., Huitfeldt, H., and Seglen, P. (1994). Ploidy-dependent growth and binucleation in cultured rat hepatocytes. Exp. Cell Res. 214, 551-560.
68. Mullàuer, L., Grasl-Kraupp, B., Bursch, W., and Schulte-Hermann, R. (1996). Transforming growth factor beta 1-induced cell death in preneoplastic foci of rat liver and sensitization by the antiestrogen tamoxifen. Hepatology 23, 840-847.
69. Nadal, C., and Zajdela, F. (1966). Polyploidie somatique dans le foie de rat. I. Le rôle des cellules binuclées dans la génèse des cellules polyploïdes. Exp. Cell Res. 42, 99-116.
70. Neal, G., and Butler, W. (1978). A comparison of the changes induced in rat liver by feeding low levels of aflatoxin B1 or an azo dye. Br. J. Cancer 37, 55-60.
71. Neal, G., Godoy, H., Judah, D., and Butler, W. (1976). Some effects of acute and chronic dosing of aflatoxin B1 on rat liver nuclei. Cancer Res. 36, 1771-1776.
72. Ni, N., and Yager, J. D. (1994). Comitogenic effects of estrogens on DNA synthesis induced by various growth factors in cultured female rat hepatocytes. Hepatology 19, 183-192.
73. Nuwaysir, E., Daggett, D., Jordan, V. C., and Pitot, H. C. (1995a). Phase II enzyme expression in rat liver in response to the antiestrogen tamoxifen. Cancer Res. 56, 3704-3710.
74. Nuwaysir, E., Dragan, Y., Jefcoate, C., Jordan, V. C., and Pitot, H. C. (1995b). The effects of tamoxifen administration on the expression of xenobiotic metabolizing enzymes in rat liver. Cancer Res. 55, 1780-1786.
75. O'Regan, R. M., Cisneros, A., England, G. M., MacGregor, J. I., Muenzner, H. D., Assikis, V. J., Bilmoria, M. M., Piette, M., Dragan, Y. P., Pitot, H. C., Chatterton, R., and Jordan, V. C. (1998). Growth characteristics of human endometrial cancer transplanted in athymic mice and treated with the new antiestrogens, toremifene and ICI 182,780. J. Natl. Cancer Inst., in press.
76. Pitot, H. C., Barsness, L., Goldsworthy, T., and Kitagawa, T. (1978). Biochemical characterization of the stages of hepatocarcinogenesis after a single dose of diethylnitrosamine. Nature 271, 456-458.
77. Powles, T., Jones, A., Ashley, S., O'Brien, M., Tidy, V., Treaven, J., Cosgrove, D., Nash, A., Sacks, N., Baum, M., McKinna, J., and Davey, J. (1994). The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res. Treat. 31, 73-82.
78. Robinson, S., Parker, C., and Jordan, V. C. (1990). Preclinical studies with toremifene as an antitumor agent. Breast Cancer Res. Treat. 16(Suppl.), 9-17.
79. Saeter, G., Schwarze, P., and Seglen, P. (1988a). Shift from polyploidizing to non-polyploidizing growth in carcinogen-treated rat liver. J. Natl. Cancer Inst. 80, 950-958.
80. Saeter, G., Schwarze, P., Nesland, J., Juul, N., Petersen, E., and Seglen, P. (1988b). The polyploidizing growth pattern of normal rat liver is replaced by divisional, diploid growth in hepatocellular nodules and carcinomas. Carcinogenesis 9, 939-945.
81. Saeter, G., Schwarze, P., Nesland, J., and Seglen, P. (1989). Diploid nature of hepatocellular tumors developing from transplanted preneoplastic liver cells. Br. J. Cancer 59, 198-205.
82. Sargent, L., Xu, Y.-h., Sattler, G., Meisner, L., and Pitot, H. C. (1989). Ploidy and karyotype of hepatocytes isolated from enzyme-altered foci in two different protocols of multistage hepatocarcinogenesis in the rat. Carcinogenesis 10, 387-391.
83. Sargent, L., Sattler, G., Roloff, B., Xu, Y.-h., Sattler, C., Meisner, L., and Pitot, H. C. (1992). Ploidy and specific karyotypic changes during promotion with phenobarbital, 2,5,2′,5′-tetrachlorobiphenyl, and 3,4,3′,4′-tetrachlorobiphenyl in rat liver. Cancer Res. 52, 955-962.
84. Sargent, L., Dragan, Y., Bahnub, N., Wiley, J., Sattler, C., Schroeder, P., Sattler, G., Jordan, V. C., and Pitot, H. C. (1994). Tamoxifen induces hepatic aneuploidy and mitotic spindle disruption after a single in vivo administration to Sprague-Dawley female rats. Cancer Res. 54, 3357-3360.
85. Sargent, L., Dragan, Y., Sattler, C., Bahnub, N., Sattler, G., Martin, P., Cisneros, A., Mann, J., Thorgeirsson, S., Jordan, V. C., and Pitot, H. C. (1996a). Induction of hepatic aneuploidy in vivo by tamoxifen, toremifene, and idoxifene in female Sprague-Dawley rats. Carcinogenesis 17, 1051-1056.
86. Sargent, L., Dragan, Y., Xu, Y.-h., Sattler, G., Wiley, J., and Pitot, H. C. (1996b). Karyotypic changes in a multistage model of chemical hepatocarcinogenesis in the rat. Cancer Res. 56, 2985-2991.
87. Sarofoff, M., Rabes, H., and Dormer, P. (1986). Correlations between ploidy and initiation probability determined by DNA cytophotometry in individual altered hepatic foci. Carcinogenesis 7, 1191-1196.
88. Sawada, N., and Ishikawa, T. (1988). Reduction of the potential for replicative but not unscheduled DNA synthesis in hepatocytes isolated from aged as compared to young rats. Cancer Res. 48, 1618-1622.
89. Schlatterer, B., and Paul, H. (1974). Influence of thyroid hormones on the number of nucleoli and degree of polyploidization in the rat liver. Acta Anat. 90, 563-572.
90. Schwarze, P., Pettersen, E., Shoaib, M., and Seglen, P. (1984). Emergence of a population of small, diploid hepatocytes during hepatocarcinogenesis. Carcinogenesis 5, 1267-1275.
91. Schwarze, P., Saeter, G., Armstrong, D., Cameron, R., Laconi, E., Sarma, D., Preat, V., and Seglen, P. (1991). Diploid growth pattern of hepatocellular tumors induced by various carcinogenic treatments. Carcinogenesis 12, 325-327.
92. Scott, R., Chakraborty, S., Sell, S., Hunt, J., and Dunsford, H. (1989). Change in the ploidy state of rat liver during chemical carcinogenesis and its relationship to the increased expression of alpha-fetoprotein. Cancer Res. 49, 6085-6090.
93. Seglen, P. O. (1997). DNA ploidy and autophagic protein degradation as determinants of hepatocellular growth and survival. Cell Biol. Toxicol. 13, 301-315.
94. Seglen, P., Schwarze, P., and Saeter, G. (1986). Changes in cellular ploidy and autophagic responsiveness during rat liver carcinogenesis. Toxicol. Pathol. 14, 342-348.
95. Staubli, W., Hess, R., and Weibel, E. (1996). Correlated morphometric and biochemical studies on the liver cells: Effects of phenobarbital on rat hepatocytes. J. Cell Biol. 42, 92-112.
96. Styles, J. (1993). Measurement of ploidy and cell proliferation in the rodent liver. Environ. Health Perspect. 101(S5), 67-71.
97. Styles, J., Elliott, B., Lefevre, P., Robinson, M., Pritchard, N., Hart, D., and Ashby, J. (1985). Irreversible depression in the ratio of tetraploid: Diploid liver nuclei in rats treated with 3′-methyl-4-dimethylaminobenzene (3′M). Carcinogenesis 6, 21-28.
98. Styles, J., Kelly, M., and Elcombe, C. (1987). A cytological difference between regeneration, hyperplasia, and early neoplasia in the rat liver. Carcinogenesis 8, 391-399.
99. Styles, J., Kelly, M., Pritchard, N., and Elcombe, C. (1988). A species comparison of acute hyperplasia induced by the peroxisome proliferating agents methylclophenapate: Involvement of the binucleated hepatocyte. Carcinogenesis 9, 1647-1655.
100. Styles, J., Kelly, M., Pritchard, N., and Foster, J. (1990). Effects produced by the nongenotoxic hepatocarcinogen methylclofenapate in dwarf mice: Peroxisome induction uncoupled from DNA synthesis and nuclearity changes. Carcinogenesis 11, 387-391.
101. Styles, J., Davies, A., Lim, C., deMatteis, F., Stanley, L., White, I., Yuan, Z.-X., and Smith, L. L. (1994). Genotoxicity of tamoxifen, tamoxifen epoxide, and toremifene in human lymphoblastic cells containing human cytochrome P450s. Carcinogenesis 15, 5-9.
102. Styles, J., Davies, A., Davies, R., White, I., and Smith, L. L. (1997). Clastogenic and aneugenic effects of tamoxifen and some of its analogs in hepatocytes from dosed rats and in human lymphoblastoid cells transfected with human P450 cDNAs (MCL-5 cells). Carcinogenesis 18, 303-313.
103. Sulkin, N. M. (1943). A study of the nucleus in the normal and hyperplastic liver of the rat. Am. J. Anat. 73, 107-125.
104. Tannenbaum, G., Gurd, W., Lapointe, M., and Pollak, M. (1992). Tamoxifen attenuates pulsatile growth hormone secretion: Mediated in part by somatostatin. Endocrinology 130, 3395-3402.
105. Tannenbaum, S. R. (1997). Comparative metabolism of tamoxifen and DNA adduct formation and in vitro studies on genotoxicity. Semin. Oncol. 24(Suppl. 1), 81-86.
106. Trump, D., Smith, D., Ellis, P., Rogers, M., Schold, S., Winer, E., Panella, T., Langan-Fahey, S., Jordan, V., and Fine, R. (1992). Vinblastine and high dose tamoxifen, a potential P-glycoprotein inhibitor: A phase I trial. J. Natl. Cancer Inst. 84, 1811-1816.
107. Tsutsui, T., Taguchi, S., Tanaka, Y., and Barrett, J. C. (1997). 17 beta-Estradiol, diethylstil-besterol, tamoxifen, toremifene, and ICI 164,384 induce morphological transformation and aneuploidy in cultured Syrian hamster embryo cells. Int. J. Cancer 70, 188-193.
108. Uryvaeva, I. (1981). Biological significance of liver cell ploidy: An hypothesis. J. Theor. Biol. 89, 557-571.
109. Vanchieri, C. (1992). Breast cancer study initiated in Italy. J. Natl. Cancer Inst. 84, 1555-1556.
110. White, I., deMatteis, F., Davies, A., Smith, L. L., Crofton-Sleigh, C., Venitt, S., Hewer, A., and Phillips, D. (1992). Genotoxic potential of tamoxifen and analogues in female Fischer F344/N rats, DBA/2 and C57BL/6 mice. Carcinogenesis 13, 2197-2203.
111. Wiebe, V., Osborne, K., McGuire, W., and DeGregorio, M. (1992). Identification of estrogenic tamoxifen metabolite(s) in tamoxifen-resistant human breast tumors. J. Clin. Oncol. 10, 990-994.
112. Williams, G., Iatropoulos, M., Djordjevic, M., and Kaltenberg, O. (1993). The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 14, 315-317.
113. Xu, Y.-h., Sattler, G., and Pitot, H. (1988). A method for the comparative study of replicative DNA synthesis in GGT-positive and GGT-negative hepatocytes in primary culture isolated from carcinogen-treated rats. In Vitro Cell Dev. Biol. 24, 995-1000.
114. Yager, J., and Yager, R. (1980). Oral contraceptive steroids as promoters of hepatocarcinogenesis in female Sprague-Dawley rats. Cancer Res. 40, 3680-3685.
115. Yager, J., Roebuck, B., Palusczcyk, T., and Memoli, V. (1986). Effects of ethinyl estradiol and tamoxifen on liver DNA turnover and new synthesis and appearance of gamma glutamyl transpeptidase positive foci in female rats. Carcinogenesis 7, 2007-2014.